EGFR and lung adenocarcinoma: It has been shown that a subset of patients with lung adenocarcinoma (10 to 40%) have specific active EGFR mutations, mostly in exons 18 to 21, that are associated with increased sensitivity to tyrosine-kinase inhibitors (TKIs) such as gefitinib (Iressa) or erlotinib (Tarceva).